CareDx, Inc (CDNA)

Market Cap	644.84M
Revenue (ttm)	340.83M
Net Income (ttm)	58.14M
Shares Out	53.23M
EPS (ttm)	1.00
PE Ratio	12.14
Forward PE	15.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,788,440
Open	12.49
Previous Close	12.46
Day's Range	12.04 - 12.72
52-Week Range	10.96 - 34.84
Beta	2.22
Analysts	Buy
Price Target	27.67 (+128.4%)
Earnings Date	Aug 6, 2025

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Forecast

According to 6 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $27.67, which is an increase of 128.40% from the latest price.

Price Target

$27.67

(128.40% upside)

Analyst Consensus: Buy